Trial Profile

A randomized, double-blind, confirmatory study of VN-100 in healthy elderly volunteers

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Influenza virus vaccine (Primary) ; Influenza HA vaccine (Flubio)
Indications Influenza virus infections
Focus Pharmacodynamics
Sponsors Daiichi Sankyo Company; Japan Vaccine; Kitasato Daiichi Sankyo Vaccine; Terumo

Most Recent Events

04 Nov 2015 New source identified and integrated; Japan Pharmaceutical Information Center - Clinical Trials Information record (JapicCTI142493)
04 Nov 2015 New trial record
28 Oct 2015 Primary endpoint has been met. (The difference between the seroconversion rates and the ratio of GMTs of HI antibody titer against three vaccine stains at Day 21), as per an article published in the Vaccine.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com